Korean J Med.
2010 Feb;78(2):226-230.
Autoimmune hemolytic anemia during PEG-interferon and ribavirin treatment for hepatitis C
- Affiliations
-
- 1Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. cwkim@catholic.ac.kr
Abstract
- The current best treatment for HCV infection is combination therapy with PEG-interferon and ribavirin. This combination therapy has markedly increased the number of sustained virologic responders but is associated with various side effects, especially hematological abnormalities. We recently experienced a 45-year-old man who developed PEG-interferon induced autoimmune hemolytic anemia (AIHA) and retinal premacular hemorrhage. The worsening hemolysis after ribavirin withdrawal and exclusion of other causes implicated PEG-interferon as the cause of the AIHA. To the best of our knowledge, this is the first case reported from Korea. Treatment with PEG-interferon requires careful follow-up, as it can induce or exacerbate autoimmune diseases.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Vitiligo in a Hepatitis C Patient after Pegylated Interferon Treatment
- A Case of Vasculitis in Chronic Hepatitis C Patient Treated with Pegylated Interferon Alpha-2a and Ribavirin
- Acute Pancreatitis Associated with Pegylated Interferon alpha-2b and Ribavirin Treatment of Chronic Hepatitis C
- Treatment of Chronic Hepatitis C
- A Case of Autoimmune Hemolytic Anemia Associated with Acute Viral Hepatitis B
